Rice Hall James & Associates LLC Cuts Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Rice Hall James & Associates LLC lessened its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 2.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 92,658 shares of the company’s stock after selling 2,078 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Travere Therapeutics were worth $1,614,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. R Squared Ltd purchased a new position in Travere Therapeutics in the 4th quarter worth approximately $53,000. CWM LLC grew its stake in Travere Therapeutics by 158.5% in the 3rd quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after buying an additional 3,065 shares in the last quarter. Quarry LP purchased a new position in Travere Therapeutics in the 3rd quarter worth approximately $105,000. Baader Bank Aktiengesellschaft purchased a new position in Travere Therapeutics in the 4th quarter worth approximately $192,000. Finally, Aigen Investment Management LP purchased a new position in Travere Therapeutics in the 3rd quarter worth approximately $170,000.

Travere Therapeutics Price Performance

NASDAQ:TVTX opened at $22.66 on Wednesday. The company has a fifty day moving average of $19.38 and a 200 day moving average of $16.38. Travere Therapeutics, Inc. has a 52 week low of $5.12 and a 52 week high of $25.29. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96.

Insider Activity at Travere Therapeutics

In other Travere Therapeutics news, CAO Sandra Calvin sold 54,244 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total value of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares in the company, valued at approximately $1,360,250. This represents a 49.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP William E. Rote sold 2,437 shares of the company’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $19.46, for a total transaction of $47,424.02. Following the completion of the transaction, the senior vice president now owns 83,170 shares of the company’s stock, valued at $1,618,488.20. This trade represents a 2.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 218,425 shares of company stock worth $4,674,259 in the last three months. 4.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TVTX. Canaccord Genuity Group boosted their price objective on shares of Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, February 12th. Evercore ISI boosted their price objective on shares of Travere Therapeutics from $33.00 to $45.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Cantor Fitzgerald began coverage on shares of Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating for the company. HC Wainwright boosted their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Finally, Barclays boosted their price objective on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.77.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.